Pacira BioSciences (PCRX) Income from Continuing Operations: 2009-2024
Historic Income from Continuing Operations for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to -$99.6 million.
- Pacira BioSciences' Income from Continuing Operations rose 103.79% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 123.63%. This contributed to the annual value of -$99.6 million for FY2024, which is 337.30% down from last year.
- Pacira BioSciences' Income from Continuing Operations amounted to -$99.6 million in FY2024, which was down 337.30% from $42.0 million recorded in FY2023.
- Over the past 5 years, Pacira BioSciences' Income from Continuing Operations peaked at $145.5 million during FY2020, and registered a low of -$99.6 million during FY2024.
- In the last 3 years, Pacira BioSciences' Income from Continuing Operations had a median value of $15.9 million in 2022 and averaged -$13.9 million.
- As far as peak fluctuations go, Pacira BioSciences' Income from Continuing Operations surged by 1,421.01% in 2020, and later tumbled by 337.30% in 2024.
- Yearly analysis of 5 years shows Pacira BioSciences' Income from Continuing Operations stood at $145.5 million in 2020, then tumbled by 71.15% to $42.0 million in 2021, then tumbled by 62.10% to $15.9 million in 2022, then surged by 163.72% to $42.0 million in 2023, then slumped by 337.30% to -$99.6 million in 2024.